Evolus, Inc. (NASDAQ:EOLS – Get Rating) Director Robert Hayman bought 1,091 shares of the firm's stock in a transaction on Monday, September 12th. The shares were acquired at an average price of $10.78 per share, for a total transaction of $11,760.98. Following the transaction, the director now owns 10,000 shares in the company, valued at $107,800. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Robert Hayman also recently made the following trade(s):

• On Friday, September 9th, Robert Hayman bought 8,909 shares of Evolus stock. The shares were acquired at an average price of $10.35 per share, for a total transaction of $92,208.15.
• On Wednesday, September 7th, Robert Hayman purchased 4,967 shares of Evolus stock. The shares were purchased at an average price of $10.05 per share, for a total transaction of $49,918.35.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $10.16 on Friday. The company has a market cap of $569.93 million, a price-to-earnings ratio of -7.21 and a beta of 2.01. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.60 and a quick ratio of 2.36. The firm has a 50 day simple moving average of $10.86 and a 200 day simple moving average of $11.30. Evolus, Inc. has a one year low of $5.06 and a one year high of $14.34.

Wall Street Analyst Weigh In

Hedge Funds Weigh In On Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Deerfield Management Company L.P. Series C lifted its stake in Evolus by 195.5% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,632,751 shares of the company's stock valued at $42,140,000 after purchasing an additional 2,403,517 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in Evolus by 521.0% in the 4th quarter. Stonepine Capital Management LLC now owns 1,863,096 shares of the company's stock valued at $12,129,000 after purchasing an additional 1,563,096 shares during the last quarter. AIGH Capital Management LLC bought a new position in Evolus in the 1st quarter valued at approximately $10,249,000. First Manhattan Co. lifted its stake in Evolus by 22.5% in the 1st quarter. First Manhattan Co. now owns 4,084,938 shares of the company's stock valued at $45,833,000 after purchasing an additional 750,022 shares during the last quarter. Finally, Schroder Investment Management Group lifted its stake in Evolus by 37.8% in the 4th quarter. Schroder Investment Management Group now owns 2,317,281 shares of the company's stock valued at $15,085,000 after purchasing an additional 636,109 shares during the last quarter. Institutional investors own 50.60% of the company's stock.

About Evolus

(Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Articles

• Get a free copy of the StockNews.com research report on Evolus (EOLS)
• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week
• Why Medical Products Maker Repligen May Be A Potential Buy
• At 10%, Is Arbor Realty Trust Dividend Worth It?
• Investors Should Tune Into RF Industries

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.